Abstracts tagged "pregnancy and systemic lupus erythematosus (SLE)"

Abstract Number: 1852 • 2018 ACR/ARHP Annual Meeting
Pregnancy in Lupus: 17-Year U.S. Nationwide Trend in Obstetric and Maternal Outcomes
Yiming Luo¹, Jiehui Xu² and Bella Y. Mehta^3,4, ¹Department of Medicine, Mount Sinai St Luke's and Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, NY, ³Hospital for Special Surgery/Weill Cornell Medicine/Mailman School of Public Health, New York, NY, ⁴Patient Oriented Research Program, Columbia University Mailman School of Public Health, New York, NY
Background/Purpose: Pregnancies in systemic lupus erythematosus (SLE) are considered high risk and associated with medical and obstetric complications [1]. Our objective was to study the…
Abstract Number: 1854 • 2018 ACR/ARHP Annual Meeting
SLE Flares during and after Pregnancy Are Mild and Occur at Similar Rates
Julia Davis-Porada¹, Sam Stern², Marta M. Guerra³, Carl Laskin^4,5, Michelle Petri⁶, Michael Lockshin⁷, Lisa R Sammaritano^8,9, David Branch^10,11, Allen D. Sawitzke¹², Joan T. Merrill^13,14, Jill P. Buyon¹⁵, Mimi Kim¹⁶ and Jane E. Salmon^8,9, ¹Research, Hospital for Special Surgery, New York, NY, ²Albert Einstein College of Medicine, New York, NY, ³Department of Medicine and Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, ⁴Mount Sinai Hospital Toronto, Toronto, ON, Canada, ⁵Trio Fertility, Toronto, ON, Canada, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Barbara Volcker Center, Hospital for Special Surgery, New York, NY, ⁸Hospital for Special Surgery, New York, NY, ⁹Weill Cornell Medicine, New York, NY, ¹⁰Intermountain Healthcare, Salt Lake City, UT, ¹¹Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT, ¹²Rheumatology, University of Utah Health Sciences Center, Salt Lake City, UT, ¹³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Medicine, New York University School of Medicine, New York, NY, ¹⁶Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionally affects women of childbearing age. Low disease activity for 6 months prior to conception leads to the best outcomes;…
Abstract Number: 2417 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Systemic Lupus Erythematous and Pre-Systemic Lupus Erythematous: A Population-Based Cohort Study
A. Nicole Wade¹, Mary A. De Vera², Eric C. Sayre³ and J. Antonio Avina-Zubieta⁴, ¹Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The adverse effects of systemic lupus erythematosus (SLE) on maternal and fetal outcomes in pregnancy have been explored mainly in clinic-based cohorts. However, data…
Abstract Number: 2423 • 2018 ACR/ARHP Annual Meeting
Births to Women with Systemic Lupus Erythematosus Can be Identified Accurately in the Electronic Health Record
Ashley Blaske¹, Amanda M. Eudy², Jim C. Oates³, Megan E. B. Clowse² and April Barnado⁴, ¹Medicine and Pediatrics, Vanderbilt University Medical Center, Nashville, TN, ²Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, ³Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Studying births in women with systemic lupus erythematosus (SLE) is difficult given its rarity and the challenges of randomized trials. While the electronic health…
Abstract Number: 6 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in a Cohort of Women with Antiphospholipid Syndrome. 25- Years Long-Term Observation
Dana Tegzova¹, Katerina Andelova², Iva Kucerova², Vera Vlasakova³, Stejskal Jan⁴, Putova Ivana⁵, Marta Olejarova⁶ and Ctibor Dostál⁷, ¹Clinical Department, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, ²Institute of Mother and Child Care, Prague, Prague, Czech Republic, ³Dept.of Internal Medicine, City Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic, ⁴1st Medical Faculty, Dpt. of Pathology, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Dpt. of Immunology, Prague, Czech Republic, ⁶Clinical, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic
Background/Purpose: The goal of this long-term project was to investigate the course of pregnancy in patients with APS (primary or secondary with SLE) in 1993-2017,…
Abstract Number: 1297 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine in Lupus Pregnancy: A Meta-Analysis of Individual Participant Data
Amanda M. Eudy¹, Michelle Petri², Rebecca Fischer-Betz³, Abeer Mokbel⁴, Cecilia Nalli⁵, Laura Andreoli⁵, Angela Tincani⁶, Yair Molad⁷, Stephen Balevic⁸ and Megan E. B. Clowse¹, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Rheumatology and Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany, ⁴Department of Rheumatology and Rehabilitation, Cairo University Hospital, Cairo, Egypt, ⁵Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶Spedali Civili and University of Brescia, Brescia, Italy, ⁷Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁸Rheumatology, Adult and Pediatric, Duke University Medical Center, Durham, NC
Background/Purpose: Our current knowledge about how to treat lupus in pregnancy derives from small prospective or retrospective cohorts, and how best to manage lupus nephritis…
Abstract Number: 2044 • 2016 ACR/ARHP Annual Meeting
Effect of Pregnancy on Disease Flares in Patients with Systemic Lupus Erythematosus
Amanda M. Eudy^1,2, Anna Maria Siega-Riz², Stephanie Engel², Nora Franceschini², Annie Green Howard³, Megan E. B. Clowse¹ and Michelle Petri⁴, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: There are conflicting results about the effect pregnancy has on the health of systemic lupus erythematosus (SLE) women. The objective of the current analysis…
Abstract Number: 2433 • 2016 ACR/ARHP Annual Meeting
Trends in Use of Hydroxychloroquine during Pregnancy in SLE Patients from 2001 to 2012
Bonnie L. Bermas¹, Seoyoung Kim^2,3, Krista Huybrechts⁴, Sonia Hernandez-diaz⁵, Brian T. Bateman⁶ and Rishi J. Desai⁷, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁵Harvard School of Public Health, Boston, MA, ⁶Division of Pharmacoepidemiology and Pharocoeconomics, Brigham and Women's Hospital, Boston, MA, ⁷PharmacoEpidemiology & PharmacoEconomics, Brigham & Women's Hospital, Boston, MA
Background/Purpose : Data suggest that hydroxychloroquine (HCQ) use during systemic lupus erythematosus (SLE) pregnancies improves outcomes. In the past decade, single-center studies report that a…
Abstract Number: 2438 • 2016 ACR/ARHP Annual Meeting
Increased Risk of Postpartum Depression in SLE Pregnancies
Evelyne Vinet¹, Susan Scott², Debbie Ehrmann Feldman³, Christian A. Pineau⁴ and Sasha Bernatsky², ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³School of Rehabilitation, Université de Montréal, Montreal, QC, Canada, ⁴McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Chronic diseases have been shown to be a strong risk factor for postpartum depression. Although there is a 2-fold increased risk of major depression…
Abstract Number: 2537 • 2015 ACR/ARHP Annual Meeting
Prescription Medication Use in Sweden Among Pregnant Women with Systemic Lupus Erythematosus and General Population Comparators
Kristin Palmsten¹, Julia F Simard^2,3, Christina D Chambers^1,4 and Elizabeth V Arkema⁵, ¹Department of Pediatrics, University of California, San Diego, La Jolla, CA, ²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ³Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁵Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: There is limited information regarding medication use patterns among pregnant women with systemic lupus erythematosus (SLE). We aimed to characterize trends of medications used…
Abstract Number: 2538 • 2015 ACR/ARHP Annual Meeting
A Population-Based Assessment of Induced Abortions in Women with Systemic Lupus Erythematosus
Evelyne Vinet¹, Emily McDonald², Susan Scott³, Christian A. Pineau¹ and Sasha Bernatsky⁴, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²McGill University, Montreal, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: SLE women with unplanned pregnancies might be at increased risk of both disease and pregnancy complications. Until now, there has been no population-based estimate…
Abstract Number: 1996 • 2015 ACR/ARHP Annual Meeting
Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies
Jane E. Salmon^1,2, Mimi Kim³, Marta Guerra⁴, Elianna Kaplowitz¹, Carl Laskin⁵, Michelle Petri⁶, Ware D. Branch^7,8, Michael Lockshin⁹, Lisa R. Sammaritano², Joan T. Merrill¹⁰, Mary D. Stephenson¹¹, Munther Khamashta¹², Alan M. Peaceman¹³, Anne Lynch¹⁴ and Jill P. Buyon¹⁵, ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁴Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁵Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷University of Utah, Salt Lake City, UT, ⁸Intermountain Healthcare, Salt Lake City, UT, ⁹Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹University of Illinois College of Medicine, Chicago, IL, ¹²Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ¹³Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁴Colorado School of Public Health, Aurora, CO, ¹⁵NYU School of Medicine, New York, NY
Background/Purpose: Women with SLE and/or aPL antibodies (SLE/APL) are at increased risk for adverse pregnancy outcomes (APO) yet identification of those destined for complications remains…
Abstract Number: 2120 • 2015 ACR/ARHP Annual Meeting
Alterations in Complement C3 and iC3b in SLE Pregnancies
Marta M. Guerra¹, Martin Schmidt², Elianna Kaplowitz³, Vibeke Strand⁴ and Jane E. Salmon⁵, ¹Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ²Kypha, Inc., St. Louis, MO, ³Hospital for Special Surgery, New York, NY, ⁴Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA, ⁵Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Pregnancy in patients with SLE is associated with increased risk of maternal and fetal complications. Studies in experimental models and humans suggest that complement…
Abstract Number: 2121 • 2015 ACR/ARHP Annual Meeting
Placentas of Lupus Pregnancies Are Characterized By Marked Inflammatory Changes Despite Good Disease Control
Wendy Marder¹, Jason S. Knight², Mariana J. Kaplan³, Emily C. Somers⁴, Xu Zhang⁴, Alexander A. O'Dell⁵, Vasantha Padmanabhan⁴ and Richard W. Lieberman⁴, ¹Div of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴University of Michigan, Ann Arbor, MI, ⁵Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of adverse pregnancy outcomes (APO), including preeclampsia and intrauterine growth restriction. While significant placental…
Abstract Number: 2200 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository Cluster Analysis: Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Female Patients
Stephane Zuily¹, Cecilia B. Chighizola², DENIS WAHL¹, Pier Luigi Meroni³ and Doruk Erkan⁴, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France, ²Department of Clinical Sciences and Community Health, University of Milan, Istituto Auxologico Italiano, Cusano Milanino, Italy, ³University of Milan, Department of Clinical Sciences and Community Health, Division of Rheumatology, Gaetano Pini Institute, Milan, Italy, ⁴Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of persistently antiphospholipid antibodies (aPL)-positive patients ± autoimmune disorders over…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].